An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets

Movement Disorders

Volumn 11, Issue 2, 1996, Pages 125-135

  Smith, Lance ^a   De Salvia, Maria ^a   Jenner, Peter ^a   Marsden, C David ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Common marmosets; Locomotor activity behavioural deficits; Parkinson's disease; Piribedil

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; PIRIBEDIL;

ALERTNESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AWARENESS; BRADYKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, ORAL; ANIMALS; ANTIEMETICS; ANTIPARKINSON AGENTS; CALLITHRIX; DOMPERIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; LOCOMOTION; MALE; MOTOR SKILLS; PARKINSON DISEASE, SECONDARY; PIRIBEDIL; PREMEDICATION; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR;

EID: 0029989550     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110203     Document Type: Article

References (21)

1. Goldstein M, Battista AF, Ohmoto T, Anagnoste B, Fuxe K. Tremor and involuntary movements in monkeys: effect of L-Dopa and a dopamine receptor stimulating agent. Science 1972;179:816-817.
2. 14C]-dopamine synthesis in the rat striatum. J Pharm Pharmacol 1973;25: 348-351.
3. Creese I. Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. Eur J Pharmacol 1974;28:55-58.
4. 3H]-N, n-propylnorapomorphine. Eur J Pharmacol 1983;87:85-94.
5. Iversen LL, Horn AS, Miller RJ. Actions of dopaminergic agonists on cyclic AMP production in rat brain homogenates. Adv Neurol 1975;9:175-212.
6. Corrodi H, Famebo L-O, Fuxe K, Hamberger B, Ungerstedt U. ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol 1972;20:195-204.
7. Costall B, Naylor RJ. Actions of dopamine agonists on motor function. Adv Neurol 1975;9:285-297.
8. Corrodi H, Fuxe K, Ungerstedt U. Evidence for a new type of dopamine receptor stimulating agent. J Pharm Pharmacol 1971;23:989-991.
9. Costall B, Naylor RJ. The site and mode of action of ET495 for the mediation of stereotyped behaviour in the rat. Naunyn Schmiedebergs Arch Pharmacol 1973;278:117-133.
10. Sweet RD, Wasterlain CG, Mc Dowell FH. Piribedil, a dopamine agonist in Parkinson's disease. Clin Pharmacol Ther 1974;16:1077-1082.
11. McDowell FH, Sweet R. Actions of dopaminergic agonists in parkinsonism. Adv Neurol 1975;9:367-371.
12. Rondot P, Bathien N, Ribadeau Dumas JL. Indications of piribedil in L-Dopa treated parkinsonian patients: physiopathologic implications. Adv Neurol 1975;9:373-381.
13. Rinne UK, Sonninen V, Marttila R. Dopaminergic agonist effects on parkinsonian clinical features and brain monoamine metabolism. Adv Neurol 1975;9:383-392.
14. Bloem BR, Irwin I, Buruma OJS, et al. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's Disease. J Neurol Sci 1990;97:273-293.
15. Tarsy D, Parkes JD, Marsden CD. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1975;38:331-335.
16. Quinn N, Illas A, Lhermitte F, Agid Y. Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology 1981;31:662-667.
17. Parkes JD. Domperidone in Parkinson's disease. Handbook Exp Pharmacol 1989;88:515-530.
18. Loschmann P-A, Smith LA, Lange KW, Jaehnig P, Jenner P, Marsden CD. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs in MPTP-treated common marmosets. Psychopharmacology 1992; 109:49-56.
19. Sarati S, Guiso G, Garattini S, Caccia S. Kinetics of piribedil and effect on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats. Psychopharmacology 1991;105:541-545.
20. Agnoli A, Baldassarre M, Del Roscio, Palesse N, Ruggieri S. Piribedil and Parkinson's disease: protection of peripheral side-effects by domperidone. Clin Pharmacol 1981;2:117-122.
21. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease. J Neurol 1992;239(suppl 1):S28-S34.